PMID- 30543451
OWN - NLM
STAT- MEDLINE
DCOM- 20190513
LR  - 20200225
IS  - 1557-7708 (Electronic)
IS  - 1075-5535 (Print)
IS  - 1075-5535 (Linking)
VI  - 25
IP  - 4
DP  - 2019 Apr
TI  - Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.
PG  - 392-397
LID - 10.1089/acm.2018.0437 [doi]
AB  - OBJECTIVES: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that 
      is found in plants of the genus Cannabis. Preclinical research has suggested that 
      CBD may have a beneficial effect in rodent models of post-traumatic stress 
      disorder (PTSD). This effect is believed to be due to the action of CBD on the 
      endocannabinoid system. CBD has seen a recent surge in research regarding its 
      potential value in a number of neuro-psychiatric conditions. This is the first 
      study to date examining the clinical benefit of CBD for patients with PTSD. 
      METHODS: This retrospective case series examines the effect of oral CBD 
      administration on symptoms of PTSD in a series of 11 adult patients at an 
      outpatient psychiatry clinic. CBD was given on an open-label, flexible dosing 
      regimen to patients diagnosed with PTSD by a mental health professional. Patients 
      also received routine psychiatric care, including concurrent treatment with 
      psychiatric medications and psychotherapy. The length of the study was 8 weeks. 
      PTSD symptom severity was assessed every 4 weeks by patient-completed PTSD 
      Checklist for the DSM-5 (PCL-5) questionnaires. RESULTS: From the total sample of 
      11 patients, 91% (n = 10) experienced a decrease in PTSD symptom severity, as 
      evidenced by a lower PCL-5 score at 8 weeks than at their initial baseline. The 
      mean total PCL-5 score decreased 28%, from a mean baseline score of 51.82 down to 
      37.14, after eight consecutive weeks of treatment with CBD. CBD was generally 
      well tolerated, and no patients discontinued treatment due to side effects. 
      CONCLUSIONS: Administration of oral CBD in addition to routine psychiatric care 
      was associated with PTSD symptom reduction in adults with PTSD. CBD also appeared 
      to offer relief in a subset of patients who reported frequent nightmares as a 
      symptom of their PTSD. Additional clinical investigation, including double-blind, 
      placebo-controlled trials, would be necessary to further substantiate the 
      response to CBD that was observed in this study.
FAU - Elms, Lucas
AU  - Elms L
AD  - 1 Rocky Vista University, Osteopathic Medical Student IV, Parker, CO.
FAU - Shannon, Scott
AU  - Shannon S
AD  - 2 Department of Psychiatry, University of Colorado Denver, Denver, CO.
FAU - Hughes, Shannon
AU  - Hughes S
AD  - 3 School of Social Work, Colorado State University College of Health and Human 
      Sciences, Fort Collins, CO.
FAU - Lewis, Nicole
AU  - Lewis N
AD  - 4 Department of Naturopathic Medicine, Wholeness Center, Fort Collins, CO.
LA  - eng
PT  - Journal Article
DEP - 20181213
PL  - United States
TA  - J Altern Complement Med
JT  - Journal of alternative and complementary medicine (New York, N.Y.)
JID - 9508124
RN  - 19GBJ60SN5 (Cannabidiol)
SB  - IM
CIN - J Altern Complement Med. 2020 Apr;26(4):349-350. PMID: 31825237
CIN - J Altern Complement Med. 2020 Apr;26(4):259-260. PMID: 32109134
MH  - Administration, Oral
MH  - Adult
MH  - Anxiety
MH  - Cannabidiol/administration & dosage/*therapeutic use
MH  - Dreams
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stress Disorders, Post-Traumatic/*drug therapy/epidemiology
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6482919
OTO - NOTNLM
OT  - PTSD
OT  - anxiety
OT  - cannabidiol
OT  - cannabis
OT  - nightmares
OT  - post-traumatic stress disorder
COIS- S.S., MD has published four professional books in the area of Integrative Mental 
      Health. Dr. S.S. is a Principal Investigator for a Phase III study of MDMA 
      assisted psychotherapy for severe PTSD and receives compensation for his clinical 
      work from a nonprofit corporation, the Multidisciplinary Association for 
      Psychedelic Studies. Dr. S.H., Dr. N.L., and Mr. L.E. report no competing 
      financial interests.
EDAT- 2018/12/14 06:00
MHDA- 2019/05/14 06:00
PMCR- 2019/04/09
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/05/14 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
PHST- 2019/04/09 00:00 [pmc-release]
AID - 10.1089/acm.2018.0437 [pii]
AID - 10.1089/acm.2018.0437 [doi]
PST - ppublish
SO  - J Altern Complement Med. 2019 Apr;25(4):392-397. doi: 10.1089/acm.2018.0437. Epub 
      2018 Dec 13.